CR20200552A - Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe - Google Patents
Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripeInfo
- Publication number
- CR20200552A CR20200552A CR20200552A CR20200552A CR20200552A CR 20200552 A CR20200552 A CR 20200552A CR 20200552 A CR20200552 A CR 20200552A CR 20200552 A CR20200552 A CR 20200552A CR 20200552 A CR20200552 A CR 20200552A
- Authority
- CR
- Costa Rica
- Prior art keywords
- soft gel
- cold
- gel capsule
- flu
- high concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
Abstract
La presente divulgación proporciona formulaciones farmacéuticas en suspensión para medicamentos para el resfriado y la gripe, específicamente formulaciones para suspensiones y formas de dosificación de cápsulas de gel blandas que tienen un tamaño reducido. La presente divulgación también proporciona métodos para preparar las suspensiones y formas de dosificación de cápsulas de gel blanda.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862672457P | 2018-05-16 | 2018-05-16 | |
US201962816727P | 2019-03-11 | 2019-03-11 | |
PCT/US2019/032017 WO2019222100A1 (en) | 2018-05-16 | 2019-05-13 | High concentration suspension formulation for cold and flu soft gel capsule medications |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20200552A true CR20200552A (es) | 2021-05-13 |
Family
ID=66690971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20200552A CR20200552A (es) | 2018-05-16 | 2019-05-13 | Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe |
Country Status (7)
Country | Link |
---|---|
US (1) | US11911517B2 (es) |
EP (1) | EP3793535A1 (es) |
CA (1) | CA3100314A1 (es) |
CR (1) | CR20200552A (es) |
MX (1) | MX2020012233A (es) |
NI (1) | NI202000082A (es) |
WO (1) | WO2019222100A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4274560A1 (en) * | 2021-01-11 | 2023-11-15 | Bayer HealthCare LLC | Concentrated liquid gel formulations containing naproxen salts |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4115315A (en) * | 1977-02-16 | 1978-09-19 | Ncr Corporation | Pearlescent capsules and process for their preparation |
GB8305693D0 (en) * | 1983-03-02 | 1983-04-07 | Scherer Ltd R P | Pharmaceutical compositions |
NL8520012A (nl) * | 1984-02-08 | 1986-01-02 | Scherer Corp R P | Aceetaminofeen gelatinecapsule, die snelle aanvang van therapeutische activiteit na orale toediening oplevert. |
US5071643A (en) | 1986-10-17 | 1991-12-10 | R. P. Scherer Corporation | Solvent system enhancing the solubility of pharmaceuticals for encapsulation |
WO1994008551A2 (en) | 1992-10-09 | 1994-04-28 | The Procter & Gamble Company | Pharmaceutical compositions and methods for treating cold symptoms |
US5505961A (en) | 1993-08-05 | 1996-04-09 | R. P. Scherer Corporation | Gelatin capsules containing a highly concentrated acetaminophen solution |
US5510389A (en) | 1994-03-02 | 1996-04-23 | The Procter & Gamble Company | Concentrated acetaminophen solution compositions |
EP0833621B1 (en) * | 1995-06-09 | 2002-01-30 | R.P. Scherer Technologies, Inc. | Soft gelatin capsules containing particulate material |
US6287985B1 (en) | 1995-10-27 | 2001-09-11 | Honeywell International Inc. | Process for applying a molten droplet coating for integrated circuits |
US5759579A (en) | 1996-12-05 | 1998-06-02 | American Home Products Corporation | Pharmaceutical suspension systems |
US6221391B1 (en) | 1998-11-23 | 2001-04-24 | Accucaps Industries Limited | Self-emulsifying ibuprofen solution and soft gelatin capsule for use therewith |
US6846495B2 (en) | 1999-01-11 | 2005-01-25 | The Procter & Gamble Company | Compositions having improved delivery of actives |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
FR2809619B1 (fr) | 2000-06-06 | 2004-09-24 | Pharmatop | Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention |
US6387400B1 (en) | 2000-08-29 | 2002-05-14 | R.P. Scherer Technologies, Inc. | Process for preparing pharmaceutical compositions for use with soft gelatin formulations |
US7029698B2 (en) | 2001-11-21 | 2006-04-18 | R.P. Scherer Technologies, Inc. | Acetaminophen compositions |
US20040162273A1 (en) | 2003-01-23 | 2004-08-19 | The Procter & Gamble Company | Powder pharmaceutical compositions |
AU2003261633A1 (en) | 2003-02-12 | 2004-09-06 | R And P Korea Co., Ltd. | Solvent system of hardly soluble drug with improved elution rate |
US20050249802A1 (en) | 2004-05-06 | 2005-11-10 | The Procter & Gamble Company | Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients |
US10022339B2 (en) | 2006-04-21 | 2018-07-17 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
US20070249727A1 (en) | 2006-04-21 | 2007-10-25 | The Proctor & Gamble Company | Compositions and kits useful for treatment of respiratory illness |
US20070254027A1 (en) | 2006-04-28 | 2007-11-01 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
US20080014275A1 (en) | 2006-07-13 | 2008-01-17 | Buehler Gail K | Pharmaceutical suspensions and related methods |
US20080014274A1 (en) | 2006-07-14 | 2008-01-17 | Wyeth | Enhanced stability phenylephrine liquid compositions |
US20110020440A1 (en) * | 2007-11-19 | 2011-01-27 | Cadila Pharmaceuticals Limited | Stable solutions of sparingly soluble actives |
US8518439B2 (en) | 2008-12-03 | 2013-08-27 | Novartis Ag | Liquid therapeutic composition |
CA2690490C (en) | 2010-01-19 | 2012-06-26 | Accucaps Industries Limited | Pharmaceutical formulations of loratadine for encapsulation and combinations thereof |
CA2690488C (en) | 2010-01-19 | 2013-06-11 | Accucaps Industries Limited | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof |
US10987365B2 (en) | 2012-10-01 | 2021-04-27 | Gm Pharmaceuticals, Inc. | Compositions and methods for the treatment of pain |
PL2961377T3 (pl) | 2013-02-28 | 2020-11-02 | Pf Consumer Healthcare 1 Llc | Zwiększona stabilność nowych ciekłych kompozycji |
CN103463088B (zh) * | 2013-08-16 | 2015-10-28 | 安士制药(中山)有限公司 | 一种日用治疗感冒的组合物及软胶囊 |
US9504656B2 (en) | 2013-10-21 | 2016-11-29 | Banner Life Sciences, LLC | Pharmaceutical compositions for poorly soluble active ingredients |
WO2016044805A1 (en) * | 2014-09-18 | 2016-03-24 | Virun, Inc. | Soft gel compositions and pre-gel concentrates |
WO2016084099A1 (en) * | 2014-11-25 | 2016-06-02 | Biological E Limited | Soft gelatin capsule composition of anti-tussive agents |
US20180071221A1 (en) | 2015-03-02 | 2018-03-15 | Bionpharma Healthcare Llc | Immediate release soluble ibuprofen compositions |
CA2980165C (en) | 2015-03-26 | 2021-06-15 | Patheon Softgels Inc. | Liquisoft capsules |
WO2017058836A1 (en) * | 2015-09-28 | 2017-04-06 | Puracap Pharmaceutical Llc | Soft gelatin capsules containing a mixture of analgesics and decongestants, expectorants, antitussives and/or antihistamines |
US20170095736A1 (en) | 2015-10-06 | 2017-04-06 | Giovanni Maria Giro | SYSTEM, METHOD, and COMPUTER PROGRAM FOR PROVIDING A TIME BASED MEDIA CONTEST PLATFORM |
US20200022932A1 (en) | 2017-03-27 | 2020-01-23 | Puracap Pharmaceutical Llc | Formulations Containing Expectorants or Decongestants |
-
2019
- 2019-05-13 WO PCT/US2019/032017 patent/WO2019222100A1/en unknown
- 2019-05-13 CR CR20200552A patent/CR20200552A/es unknown
- 2019-05-13 EP EP19728187.6A patent/EP3793535A1/en active Pending
- 2019-05-13 MX MX2020012233A patent/MX2020012233A/es unknown
- 2019-05-13 US US16/410,599 patent/US11911517B2/en active Active
- 2019-05-13 CA CA3100314A patent/CA3100314A1/en active Pending
-
2020
- 2020-11-16 NI NI202000082A patent/NI202000082A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20190350865A1 (en) | 2019-11-21 |
WO2019222100A1 (en) | 2019-11-21 |
MX2020012233A (es) | 2021-01-29 |
US11911517B2 (en) | 2024-02-27 |
NI202000082A (es) | 2021-03-11 |
CA3100314A1 (en) | 2019-11-21 |
EP3793535A1 (en) | 2021-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20200064A (es) | Carboxamidas como moduladores de los canales de sodio | |
AR122746A2 (es) | Una formulación farmacéutica líquida estable de anticuerpo | |
NZ743964A (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
PH12018502438A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12021550992A1 (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
MA40539A (fr) | Procédés de formulation de compositions de conjugués anticorps-médicaments | |
PH12019502444A1 (en) | Formulations of human anti-rankl antibodies, and methods of using the same | |
MX2022001146A (es) | Formulaciones de anticuerpos anti-pvrig y sus usos. | |
PH12020551716A1 (en) | Anti-ror antibody constructs | |
CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
NZ702342A (en) | Pharmaceutical formulation | |
MX2022007391A (es) | Compuestos activos frente a receptores nucleares. | |
MX2022007265A (es) | Compuestos activos frente a receptores nucleares. | |
CR20210435A (es) | Formulación de anticuerpos terapéuticos | |
MX2022000712A (es) | Moduladores de nlrp3. | |
MX2020005373A (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis. | |
MX2020012233A (es) | Formula de suspension de alta concentracion para medicamentos en capsula de gel blanda para resfriado y gripe. | |
MX2020000009A (es) | Nuevas formulaciones en capsulas de gelatina blandas de secnidazol y sus usos. | |
EP3648745A4 (en) | PHARMACEUTICAL COMPOSITION CONSISTING OF A MULTI-UNIT SPHEROIDAL TABLET CONTAINING ESOMEPRAZOLE AND A PHARMACEUTICAL SALT OF THE SAME, AND PROCESS FOR THE PREPARATION OF THE PHARMACEUTICAL COMPOSITION | |
MX2022000803A (es) | Formulaciones de capsula de cubierta blanda y metodos de preparacion y uso de las mismas. | |
MX2021008941A (es) | Moduladores gpr35. | |
MX2017015202A (es) | Formulaciones liquidas de celecoxib para administracion oral. | |
PH12018502139A1 (en) | Phosphaplatin liquid formulations | |
MX2018005226A (es) | Formulaciones de anticuerpo anti-factor d. |